✦ LIBER ✦

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer

✍ Scribed by Lartigau, Eric F.; Tresch, Emmanuelle; Thariat, Juliette; Graff, Pierre; Coche-Dequeant, Bernard; Benezery, Karen; Schiappacasse, Luis; Degardin, Marian; Bondiau, Pierre-Yves; Peiffert, Didier; Lefebvre, Jean-Louis; Lacornerie, Thomas; Kramar, Andrew

Book ID: 122328659
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 426 KB
Volume: 109
Category: Article
ISSN: 0167-8140
DOI: 10.1016/j.radonc.2013.08.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stereotactic body radiotherapy: An attra

Stereotactic body radiotherapy: An attractive treatment modality for recurrent head and neck carcinoma. (Regarding Lartigau et al.: Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer)

✍ Cacicedo, Jon; Bilbao, Pedro 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Salvage Stereotactic Reirradiation With

Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study

✍ Bénédicte Comet; Andrew Kramar; Mathieu Faivre-Pierret; Sylvain Dewas; Bernard C 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 547 KB

Phase 1 trial of concurrent erlotinib, c

Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer

✍ Johnny Kao; Eric M. Genden; Chien-Ting Chen; Michael Rivera; Charles C. L. Tong; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 2 views

Phase 1 trial of combined chemotherapy a

Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer

✍ Sharon Spencer; Richard Wheeler; Glenn Peters; Ruby Meredith; Sam Beenken; Lisle 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Abstract ## Background. The management of recurrent unresectable head and neck cancer remains a challenging problem. Based on the circadian rhythm concept, we sought to determine the maximum tolerated dose (MTD) of infusional 5‐flourouracil (5‐FU), hydroxyurea (HU), and reirradiation (RT). ##

Phase II study of rubitecan in recurrent

Phase II study of rubitecan in recurrent or metastatic head and neck cancer

✍ Francesco Caponigro; Giacomo Cartenì; Jean Pierre Droz; Amalia Milano; Wayne B. 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 236 KB

Palliative laser therapy for recurrent h

Palliative laser therapy for recurrent head and neck cancer: A phase II clinical study

✍ Marcos B. Paiva; Keith E. Blackwell; Romaine E. Saxton; Thomas C. Calcaterra; Pa 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 741 KB